News|Articles|April 10, 2020

EMA Sets Up COVID-19 Task Force

Author(s)Pharmaceutical Technology Editors

The task force will assist in the developing, authorizing, and monitoring of treatments of COVID-19.

To assist member states of the European Union in developing, authorizing, and monitoring treatments of COVID-19, the European Medicines Agency (EMA) has set up the COVID-19 EMA Pandemic Task Force (COVID-ETF). The task force is accountable to EMA’s Committee for Medicinal Products for Human Use (CHMP) and will include CHMP rapporteurs and co-rapporteurs and any additional experts that may be needed, the agency announced in a April 9, 2020 press release.

The COVID-ETF will review available scientific data on possible COVID-19 treatments as well as request data from developers. The task force will also offer scientific support to facilitate clinical trials of COVID-19 treatments and provide feedback on development plans. It will advise the Scientific Advice Working Party or CHMP on formal scientific advice and product-related assessment and contribute to Pharmacovigilance Risk Assessment Committee activities. It will also ensure cooperation with stakeholders and European and international organizations.

Source: EMA

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

Ravulizumab gains FDA accelerated approval for IgA nephropathy after it cut proteinuria by 43.4%.

October 22nd, 2026

Ravulizumab's IgA Nephropathy Approval Expands Large-Molecule Biologic Demand

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 20th, 2026

Drug-Device Combination Apps: The FDA's 3 Questions for Sponsors

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

October 19th, 2026

Expedited IND Pilot Targets Sequential Delays Slowing First-in-Human Trials

Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.